Dynavax Technologies Corp. (DVAX) is “One to Watch”
Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases. They discover and develop a pipeline of Toll-like Receptor (TLR) product candidates. The Company's clinical-stage product candidates include Phase 3 HEPLISAV ™ Hepatitis B Vaccine, Phase 1 Hepatitis C Therapy, and Phase 1 Hepatitis B Therapy. Dynavax Technologies Corporation trades on the NASDAQ Capital Market. The Company's lead product candidate HEPLISAV™ is a Phase 3 investigational adult hepatitis B vaccine designed to provide more rapid and increased protection with fewer doses than current licensed vaccines. Their global strategy is…